Search Results - "HRASKA, Marek"

Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines by Hensler, Michal, Rakova, Jana, Kasikova, Lenka, Lanickova, Tereza, Pasulka, Josef, Holicek, Peter, Hraska, Marek, Hrnciarova, Tereza, Kadlecova, Pavla, Schoenenberger, Andreu, Sochorova, Klara, Rozkova, Daniela, Sojka, Ludek, Drozenova, Jana, Laco, Jan, Horvath, Rudolf, Podrazil, Michal, Hongyan, Guo, Brtnicky, Tomas, Halaska, Michal J., Rob, Lukas, Ryska, Ales, Coosemans, An, Vergote, Ignace, Garg, Abhishek D., Cibula, David, Bartunkova, Jirina, Spisek, Radek, Fucikova, Jitka

“…Dendritic cells (DCs) have received considerable attention as potential targets for the development of novel cancer immunotherapies. However, the clinical…”
Get full text

Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial by Rob, Lukas, Cibula, David, Knapp, Pawel, Mallmann, Peter, Klat, Jaroslav, Minar, Lubos, Bartos, Pavel, Chovanec, Josef, Valha, Petr, Pluta, Marek, Novotny, Zdenek, Spacek, Jiri, Melichar, Bohuslav, Kieszko, Dariusz, Fucikova, Jitka, Hrnciarova, Tereza, Korolkiewicz, Roman Pawel, Hraska, Marek, Bartunkova, Jirina, Spisek, Radek

“…BackgroundMost patients with epithelial ovarian cancer (EOC) relapse despite primary debulking surgery and chemotherapy (CT). Autologous dendritic cell…”
Get full text

Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial by Zemanova, Milada, Cernovska, Marketa, Havel, Libor, Bartek, Tomas, Lukesova, Sarka, Jakesova, Jitka, Vanasek, Jaroslav, Reiterer, Pavel, Kultan, Juraj, Andrasina, Igor, Siskova, Lenka, Koubkova, Leona, Skrickova, Jana, Salajka, Frantisek, Pesek, Milos, Klepetko, Petr, Beniak, Juraj, Fricke, Harald, Kadlecova, Pavla, Korolkiewicz, Roman P., Hraska, Marek, Bartunkova, Jirina, Spisek, Radek

“…•Dendritic cell-based immunotherapy (DCVAC/LuCa) plus a platinum doublet in NSCLC.•SLU01: a multicenter, open-label, parallel-group, randomized, phase I/II…”
Get full text

Tracking of the CaMV-35S promoter performance in GFP transgenic tobacco, with a special emphasis on flowers and reproductive organs, confirmed its predominant activity in vascular tissues by HRASKA, Marek, RAKOUSKY, Slavomir, CURN, Vladislav

“…Constitutive promoters are the most common promoters used to drive the expression of various genes in monocots and dicots. Therefore, it is of intense interest…”
Get full text

Green fluorescent protein as a vital marker for non-destructive detection of transformation events in transgenic plants by Hraska, M, Rakousky, S, Curn, V

“…Transformation of plants is a popular tool for modifying various desirable traits. Marker genes, like those encoding for bacterial β-glucuronidase (GUS),…”
Get full text

Sample topography and position within plant body influence the detection of the intensity of green fluorescent protein fluorescence in the leaves of transgenic tobacco plants by HRASKA, Marek, HERMANOVA, Veronika, RAKOUSKY, Slavomir, CURN, Vladislav

“…The effect of the type of leaf tissue selected for the study of green fluorescent protein (GFP) fluorescence intensity was investigated here using the T₁…”
Get full text

An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors by Fucikova, Jitka, Hensler, Michal, Kasikova, Lenka, Lanickova, Tereza, Pasulka, Josef, Rakova, Jana, Drozenova, Jana, Fredriksen, Tessa, Hraska, Marek, Hrnciarova, Tereza, Sochorova, Klara, Rozkova, Daniela, Sojka, Ludek, Dundr, Pavel, Laco, Jan, Brtnicky, Tomas, Praznovec, Ivan, Halaska, Michael J., Rob, Lukas, Ryska, Ales, Coosemans, An, Vergote, Ignace, Cibula, David, Bartunkova, Jirina, Galon, Jérôme, Galluzzi, Lorenzo, Spisek, Radek

“…Abstract Purpose: The successful implementation of immune checkpoint inhibitors (ICI) in the clinical management of various solid tumors has raised…”
Get full text

Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial by Cibula, David, Rob, Lukas, Mallmann, Peter, Knapp, Pawel, Klat, Jaroslav, Chovanec, Josef, Minar, Lubos, Melichar, Bohuslav, Hein, Alexander, Kieszko, Dariusz, Pluta, Marek, Spacek, Jiri, Bartos, Pavel, Wimberger, Pauline, Madry, Radoslaw, Markowska, Janina, Streb, Joanna, Valha, Petr, Hassan, Hariz Iskandar Bin, Pecen, Ladislav, Galluzzi, Lorenzo, Fucikova, Jitka, Hrnciarova, Tereza, Hraska, Marek, Bartunkova, Jirina, Spisek, Radek

“…DCVAC/OvCa is an active cellular immunotherapy designed to stimulate an immune response against ovarian cancer. We explored the safety and efficacy of…”
Get full text

Dendritic cell vaccine (DCVAC) combined with chemotherapy (CMT) in patients with newly diagnosed epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Biomarker exploratory analysis of a phase 2, open-label, randomized, multicenter trial by Rob, Lukas, Cibula, David, Knapp, Pawel, Mallmann, Peter, Klat, Jaroslav, Minar, Lubos, Bartos, Pavel, Chovanec, Josef, Valha, Petr, Pluta, Marek, Novotny, Zdenek, Spacek, Jiri, Melichar, Bohuslav, Kieszko, Dariusz, Fucikova, Jitka, Hrnciarova, Tereza, Korolkiewicz, Roman Pawel, Hraska, Marek, Bartunkova, Jirina, Spisek, Radek

“…Abstract only 5521 Background: Most patients with EOC relapse despite PDS and CMT. Autologous DCVAC can present tumor antigens to elicit a durable immune…”
Get full text